Efficacy of adoptive immunocyte infusion combined with immunodeprivation in the treatment of castration resistant prostate cancer
DOI：10.3872/j.issn.1007-385x.2020.12.012
- VernacularTitle:过继性免疫细胞输注联合免疫剥夺治疗去势抵抗性前列腺癌的疗效
- Author:
TANG Jingling1, 2
1
,
2
,
3
;
YANG Yuan1, 2,
1
,
2
,
3
;
WU Xueli2
4
;
XIU Jin2
4
;
LI Xiaoyang2
4
;
LIU Honglin2
4
;
HU Pingsheng1, 2
1
,
2
;
WU Chaoyang3
5
;
GE Huixin3
5
Author Information
1. 1. Clinical Medical Research Center, Affiliated Hospital of Guizhou Medical University, Guiyang 550004, Guizhou, China
2. 2. Cancer Biotherapy Center, Affiliated Hospital of Guizhou Medical University, Guiyang 550004, Guizhou, China
3. 3. Guizhou Provincial Cancer Hospital, Guiyang 550004, Guizhou, China
4. 2. Cancer Biotherapy Center, Affiliated Hospital of Guizhou Medical University, Guiyang 550004, Guizhou, China
5. 3. Guizhou Provincial Cancer Hospital, Guiyang 550004, Guizhou, China
- Publication Type:Journal Article
- Keywords:
castration resistant prostate cancer;
adoptive immunocyte infusion;
cytotoxic T lymphocytes;
biological immunotherapy
- From:
Chinese Journal of Cancer Biotherapy
2020;27(12):1388-1392
- CountryChina
- Language:Chinese
-
Abstract:
[Abstract] Objective: To observe the clinical effect of adoptive immunocyte infusion combined with immunodeprivation in the treatment of castration-resistant prostate cancer. Methods: The information of 35 patients with castration resistant prostate cancer, who were treated in the Affiliated Guizhou Provincial Cancer Hospital of Guizhou Medical University from 2011 to 2018 was collected. According to different treatments, these patients were divided into biotherapy group (18 cases) and non-biotherapy group (17 cases). Patients in the non-biotherapy group were treated with abiraterone or docetaxel, while the patients in biotherapy group were treated with cytotoxic T lymphocytes (CTL) in combination with cyclophosphamide (CTX). The treatment efficacy in the biotherapy group and the non-biotherapy group was evaluated by comparing the changes of prostate cancer-specific antigen (PSA), improvement of subjective indicators (bone pain, sleep, physical strength) and clinical efficacy before and after treatment. Results: (1) PSA level: after treatment, PSA was decreased in both groups; the biotherapy group had an obvious decrease (P<0.01),which was more significant than the decrease in non-biotherapy group (P<0.05). (2) Clinical efficacy: The clinical efficacy of patients after CTL treatment was significantly different from that of non-biotherapy group (P<0.01). (3) Subjective indicators: The bone pain, sleep and physical strength of the patients in the biotherapy group were significantly improved after treatment, and there was a significant difference as compared with patients of the non-biological treatment group (P<0.01). (4) Overall survival: The median survival of the patients receiving biotherapy was 4 months longer than patients from non-biological treatment group, but the difference was insignificant (P=0.3935). Conclusion: CTL combined with CTX in the treatment of castration resistant prostate cancer can significantly reduce PSA and improve the quality of life of patients.
- Full text:20201212.pdf
